Influenzavirus B Vaccine

The pursuit of health is the unremitting appeal of mankind. Vaccines have always been the focus of scientists as the most effective strategy for disease control. Creative Biolabs has extensive experience in the field of vaccines. As a provider of professional vaccine products and services, our high-quality output helps vaccine researchers around the world complete their research tasks efficiently and economically. Our expertise in the field of influenza virus vaccines will be the best assist for your influenza vaccine development.

Influenza B Virus

Influenza B virus nearly exclusively infects humans, and the only known animal that is susceptible to the virus is the seal. The virus is not as common as the influenza A virus, and the mutation rate is lower than that of the A type, and there is only one subtype in the genus. The narrow host range of Influenza B virus is probably the cause of its inability to cause large-scale influenza epidemics. According to the antigenic nature of the viral surface glycoprotein hemagglutinin, Influenza B virus can be divided into two lineages, B/Yamagata/16/88-like and B/Victoria/2/87-like viruses. It has been generally accepted that Influenza B viruses cause high morbidity and mortality worldwide, and the impact on adolescents is very serious.

The Development of Vaccines for Influenza B Virus

The prevalence of Influenza A and B viruses continues to fluctuate, with different types and subtypes of viruses prevalent in different years. Influenza B virus was popular between 1976 and 2001 for six years, accounting for more than 70% of the laboratory-confirmed flu. Due to the unpredictable prevalence of influenza virus types and subtypes, inactivated influenza vaccines must contain three strains of influenza A virus H1N1, influenza A virus H3N2, and influenza B virus. The effectiveness of such vaccines depends on how much the antigenic components of the vaccine match that of the virus circulating in the current population. The HA and NA antigens, which are vaccine targets, continue to undergo point mutations to evade the host immune system, so the vaccine formulation needs to be updated every year and re-inoculation is required.

Based on these facts, it has become a general trend to develop a universal vaccine that is effective for all influenza A and B virus subtypes and does not require regular updates to vaccine components.

The universal influenza A virus vaccine typically utilizes the extracellular domain of its highly conserved M2 protein, but the same protein is not present in the influenza B virus, making scientists less concerned about the universal influenza B vaccine. The universal subunit vaccine targeting the conserved maturational cleavage site of the hemagglutinin precursor of influenza B virus shows high immunogenicity in preclinical evaluation and protects mice from lethal-dose challenge of any lineages of influenza B virus. Therefore, it can be used as a promising universal vaccine candidate for influenza B virus.

In order to provide the world's vaccine developers with the highest quality and most reliable products and services, Creative Biolabs has established a professional vaccine research and development team. After more than ten years of unremitting efforts, we have established a scientific and comprehensive research and service system. With regard to any of your vaccine research needs, we will meet your needs with the highest quality and the most cost-efficient prices.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.